Objective-Vascular endothelial growth factor receptor 2 (VEGFR2) is a receptor tyrosine kinase that regulates vascular physiology. However, mechanism(s) by which VEGFR2 signaling and trafficking is coordinated are not clear.
V ascular endothelial growth factor A (VEGF-A) is an essential regulator of vascular physiology. 1 VEGF-A plays key roles in vasculogenesis and angiogenesis during development. 2 Angiogenesis is needed for embryogenesis and wound healing but is also associated with cancer, eye diseases, and other chronic disorders. The importance of VEGF-A is underlined by the fact that deletion of a single mouse VEGF-A allele causes embryonic lethality attributable to the impairment of vascular development. 3, 4 The VEGF-A gene gives rise to at least 6 to 12 different variants, with VEGF-A 165 (termed VEGF-A) being the most abundant and proangiogenic isoform. 5, 6 VEGF-A can bind to 2 different but closely related endothelial receptor tyrosine kinases (RTKs): fms-like tyrosine kinase (VEGFR1 or Flt-1) and kinase insert domain receptor (VEGFR2 or KDR). A major proangiogenic axis is based on VEGF-A binding to VEGFR2, stimulating tyrosine kinase activity, autophosphorylation, and signaling to downstream target proteins which regulate diverse processes including chemotaxis, migration, vascular permeability, cell survival, and proliferation. 7 Such physiological responses are regulated via multiple effectors including focal adhesion kinase (FAK), c-Akt/PKB, extracellular-signal related kinase (ERK) pathways, and stimulation of nitric oxide and prostaglandin synthesis. 8 Whereas VEGFR2 signaling pathways that regulate endothelial responses are well characterized, the spatial and temporal order underlying such events remains elusive. For example, VEGFR2 plasma membrane activation leads to trafficking to endosomes and degradation in lysosomes. 9 Simultaneously, VEGFR2 activation leads to tyrosine phosphorylation and intracellular signaling. 7, 8 How VEGFR2mediated signaling events from different intracellular locations are coordinated is not known. Increasing evidence points to the requirement for coordination of RTK trafficking with signaling from different endocytic compartments. 10, 11 RTK trafficking comprises a series of complex highly regulated events with ligand binding leading to receptor activation and rapid internalization followed by degradation that is linked to signaling attenuation. When epidermal growth factor receptor (EGFR) clathrin-dependent endocytosis is inhibited by a mutant dynamin, EGF-stimulated signaling is enhanced. 12 However, mitogen-activated protein kinase (MAPK) activation is suppressed, showing a need for EGFR trafficking. Endosome-associated EGFR can still autophosphorylate and recruit various effectors such as Grb2, a mediator of Ras and MAPK signaling. 13 Another RTK, the nerve growth factor receptor TrkA, can also form endosomal signaling complexes in neurons. 14 Receptor-ligand complexes could thus continue signaling until sequestration into the multivesicular body before recycling back to the plasma membrane or lysosomal degradation. 15, 16 Membrane trafficking, targeting, and degradation along the endocytic pathway is regulated by a wide array of regulatory molecules including GTPases, ubiquitin ligases, and clathrinand ubiquitin-binding effectors. Rabs are Ras-related small GTPases that program vesicle docking and fusion. Rab proteins can be used as tools to dissect the trafficking itinerary of different proteins associated with the exo-and endocytic pathways. [17] [18] [19] [20] We have used endocytic Rabs to test involvement in VEGFR2 trafficking and signaling in primary human endothelial cells. We show that VEGFR2 trafficking is dependent on Rab5a and Rab7a. Manipulation of Rab function indicates early or late endosome-specific modulation of VEGFR2 signaling and endothelial migration.
Methods

Materials
Chemicals and reagents were obtained from Sigma-Aldrich or Invitrogen, unless stated otherwise. Primary antibodies include mouse anti-transferrin receptor, mouse anti-EEA1, mouse anti-Rab7a (Abcam), rabbit anti-Cathepsin D (BD Transduction Labs), rabbit anti-pY1175 VEGFR2, rabbit anti-c-Akt, rabbit anti-p42/44 MAPK (Cell Signaling Technology), anti-VEGFR2, and anti-TfR antibodies. 9,21 HRP-conjugated secondary antibodies were from Jackson ImmunoResearch labs, and AlexaFluor-conjugated secondary antibodies were from Invitrogen.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords as previously described. 22, 23 HUVECs were cultured in defined endothelial cell basal medium (Promocell). Cells were seeded onto tissue culture plastic (Nunc) precoated with 0.1% (wt/vol) porcine skin gelatin. Cells were generally passaged with a dilution of 1:3 to 1:4. HUVECs were grown for up to 4 passages and exhibited characteristic cobblestone morphology and routinely checked for endothelial character using the endothelial-specific marker Von Willebrand Factor that accumulates in Weibel-Palade bodies. 22
Gene Manipulation, Transfection, and RNAi
HUVECs were transiently transfected with plasmid DNA in Opti-MEM (Invitrogen) supplemented with 10% fetal calf serum (FCS) using an EasyJECT electroporator (Flowgen). The cell suspension was then plated out and allowed to recover in complete medium for 48 hours before ligand stimulation, fixation, and processing for microscopy or lysis for Western blotting. pEGFP-Rab7a constructs were from B. van Deurs (Copenhagen, Denmark). pEGFP-Rab5a constructs were from B. Knoll (University of Houston, Texas).
HUVECs were transfected with RNAi duplexes using Lipofectamine 2000 (Invitrogen). Cells were treated and assayed 48 hours after transfection. RNAi targeting using Rab7a siRNA duplexes were designed, synthesized, and annealed by Eurogentec. RNAi sequences were designed using proprietary software (Eurogentec) and of the various siRNA duplexes tested, the best were used. Rab5a siRNA duplex sense strand was 5Ј-GUCCGCUGUUGGCAAAUCA-3Ј whereas Rab7a siRNA duplex had a sense strand was 5Ј-CUGCUGCGUUCUCCUAUUU-3Ј. Nontargeting siRNA duplex (Silencer Negative Control #1; Ambion) was also used as a negative control.
Immunofluorescence Microscopy
Cells were fixed, processed for immunofluorescence and visualized using wide-field deconvolution microscopy as described previously. 9, 22, 23 Images were subsequently converted to tif files and imported into PowerPoint. Quantification of colocalized pixels was performed using IMARIS software (Bitplane AG) on imported deconvolved 3-D datasets. Quantification of the degree of overlap between VEGFR2 and other cell markers was performed using the Coloc module in IMARIS v4.0.6 with a threshold value taken as 10% of the maximum intensity. Images of triple labeled cells were acquired using an Inverted Zeiss LSM510 META Axiovert 200 laser scanning confocal microscope (Carl Zeiss) with a 63ϫ objective. Single slice sections were imaged, averaged, and collected using Zeiss acquisition software.
Immunoblotting SDS-PAGE analysis and immunoblotting was performed as described previously. 9,22,23 A Fuji LAS-3000 system and software was used to capture chemiluminescence images, and band intensities were determined by densitometry using Advanced Image Data Analyzer (AIDA) 2.11 software (FujiFilm).
Cell Migration
Control or siRNA duplex-treated HUVECs were trypsinized and seeded at 5ϫ10 4 cells per ml into a 24-well plate with 8-m pore size Transwell inserts (Becton-Dickinson) within the upper chamber and 50 ng/mL VEGF-A in the lower chamber for migration to occur. After 16 hours, filters were fixed, stained with hematoxylin-eosin, and excised for microscopy. Random fields from each image was counted for calculation of % number of cells migrated onto filter underside versus nontreated control.
Results
VEGFR2 Early Endosome Trafficking Is Regulated by Rab5a
Our previous work showed evidence for activated VEGFR2 trafficking through the endocytic pathway before lysosomal degradation. 9 One likelihood is that such trafficking is dependent on the Rab5a GTPase that regulates early endosome fusion. 24 VEGFR2 is evident as both immature (Ϸ200 kDa) and mature glycosylated (Ϸ230 kDa) polypeptides detected in primary human endothelial cells using VEGFR2-specific antibodies to either extracellular or cytoplasmic domains ( Figure 1A ). Microscopy on nonpermeabilized or permeabilized endothelial cells showed VEGFR2 distribution at the plasma membrane and punctate endosomes (supplemental Figure I , available online at http://atvb.ahajournals.org). Expression of wild-type GFP-tagged Rab5a showed colocalization with VEGFR2 in a punctate intracellular compartment ( Figure 1B ). VEGFR2 and GFP-Rab5a showed Ϸ60% codistribution in transfected cells. VEGFR2 and Rab5a also showed colocalization with a key marker, early endosomal antigen 1 ( Figure 1B) .
A GTPase-deficient Rab5a mutant (Q79L) programs a membrane-associated state which allows plasma membrane endocytosis but stimulates endosome fusion. 25 However, Rab5aQ79L membrane association prevents endosomederived vesicle fission resulting in enlarged endosomes. 26, 27 Rab5aQ79L expression was used to investigate VEGFR2 trafficking through endosomes. Overexpression of GFP-Rab5aQ79L in endothelial cells caused enlarged endosomes which contained both EEA1 and VEGFR2 (Figure 2A ). VEGF-A stimulation for 120 minutes had no effect on VEGFR2 localization ( Figure 2B ), indicating that VEGFR2 is trapped within these endosomes in the presence of Rab5aQ79L. Quantification of cells containing both VEGFR2 and Rab5aQ79L showed a 2-fold increase in VEGFR2 labeling in VEGF-Astimulated cells compared to nonstimulated controls ( Figure  2C ). Rab5a could be depleted using RNAi, and signaling events such as VEGFR2 tyrosine phosphorylation (Ϸ1.3 fold) and MAPK p42/44 phosphorylation (Ϸ1.5-fold) were both elevated and prolonged (supplemental Figure II) . However, 15 minutes after VEGF-A stimulation, VEGFR2 phosphorylation is enhanced by Rab5a depletion (supplemental Figure II) . Thus, Rab5a GTPase activity may regulate both VEGFR2 trafficking and phosphorylation status in early endosomes.
Trafficking of VEGFR2 Through Late Endosomes Is Regulated by Rab7a
Are other GTPases are involved in VEGFR2 endosomal trafficking? The Rab7a GTPase regulates early to late endo-some trafficking including receptor tyrosine kinases such as epidermal growth factor receptor. 28 We tested a role for this GTPase using transfection of a GFP-tagged Rab7a in primary endothelial cells. We found that Rab7a in endothelial cells showed colocalization with a late endosome marker, CD63 ( Figure 3B) , and a lysosomal enzyme, cathepsin D ( Figure  3C ). However, Rab7a showed no significant colocalization with early endosome markers such as EEA1 ( Figure 3A) or the transferrin receptor, TfR ( Figure 3D ). Thus Rab7a is a marker for an endocytic compartment that is distinct from Rab5a.
We used GFP-tagged Rab7a expression in transfected endothelial cells to assess effects on endogenous VEGFR2 trafficking ( Figure 4 ). Cells were stimulated for 30 minutes or 120 minutes with VEGF-A and assessed for VEGFR2 localization in cells expressing GFP-Rab7a compared to nonstimulated controls. Cells that overexpressed wild-type Rab7a consistently displayed increased VEGFR2 staining in punctate structures resembling endosomes, 30 minutes after ligand stimulation ( Figure 4B ). Quantification shows an Ϸ4-fold increase in VEGFR2 labeling of cells overexpressing Rab7a, 30 minutes after VEGF-A stimulation ( Figure 4D ). Further stimulation with VEGF-A for 120 minutes showed a 94% decrease in VEGFR2 labeled cells during Rab7a expression (H. Jopling and S. Ponnambalam, unpublished data, 2009). This is corroborated by the decreased VEGFR2 and Rab7a colocalization after treatment with VEGF-A for 120 minutes ( Figure 4D ).
We expressed a GDP-bound Rab7aT22N mutant in endothelial cells to further check for effects on VEGFR2 trafficking and degradation ( Figure 5 ). GFP-Rab7aT22N showed a widely dispersed homogenous staining consistent with a nonmembrane or cytosolic localization ( Figure 5A through 5C). Again, VEGFR2 labeling was evident in control ( Figure  5A ) and VEGF-A-stimulated cells ( Figure 5B and 5C) in punctate structures resembling late endosomes. Interestingly, VEGFR2 labeling persisted 120 minutes after VEGF-A stimulation ( Figure 5C ), different to that observed on expression of wild-type Rab7a (Figure 4) . Expression of the GTP-bound Rab7aQ67L mutant also caused VEGFR2 accumulation in punctate endosomes after prolonged VEGF-A stimulation (supplemental Figure IIIA) . A fraction of endosomes showed colabeling of Rab7aT22N, VEGFR2 and EEA1 after VEGF-A stimulation for 120 minutes (supplemental Figure III) , indicating that endocytic trafficking of VEGFR2 was perturbed. Quantification showed Ϸ2.5-fold increase in VEGFR2 labeling in cells expressing Rab7aT22N that had been stimulated with VEGF-A for 120 minutes in comparison to nontransfected endothelial cells ( Figure 5D ).
VEGFR2 Intracellular Signaling Is Rab7a-Dependent
Increasing evidence indicates that functional RTK signaling complexes such as those involving EGFR 29 or c-Met 30 are present on endosomes. To test whether this is true for VEGFR2, we used RNAi to deplete Rab7a levels and probe for VEGFR2 signaling (Figure 6 ). Using a siRNA duplex specific for Rab7a, depletion of Ϸ65% was achieved in primary human endothelial cells compared to control mocktransfected cells (Figure 6A and 6B) . Neither control nor Rab7a-depleted cells showed tyrosine phosphorylation of residue Y1175 in VEGFR2 (pY1175) without VEGF-A stimulation ( Figure 6A, lanes 1 and 2) . However, after VEGF-A stimulation for 15 minutes, tyrosine phosphorylation of VEGFR2 (pY1175) was clearly evident ( Figure 6A,  lanes 3 and 4) . However, the VEGFR2 pY1175 epitope was decreased in Rab7a-depleted cells in comparison to controls ( Figure 6A, lanes 5 and 6) . Quantification showed Ϸ2-fold decrease in VEGFR phosphorylation (pY1175) in VEGF-Astimulated and Rab7a-depleted cells 30 minutes after VEGF-A stimulation ( Figure 3C) .
As an indicator of downstream VEGFR2 signaling, we further examined p42/44 MAPK phosphorylation in control and Rab7a-depleted cells. In resting endothelial cells, phosphorylated p42/44 MAPK was not evident ( Figure 6A, lanes  1 and 2) . However, after VEGF-A stimulation for 15 minutes, levels of the phosphorylated p42/44 MAPK epitope exhibited Ϸ11-fold increase in Rab7a-depleted cells ( Figure 6A, lane  4) . In addition, there was a dramatic increase in intracellular staining for p42/44 MAPK after VEGF-A stimulation at both 10-and 30-minute time points after VEGF-A addition (supplemental Figure IV) . Importantly, at 30 minutes after VEGF-A stimulation although p42/44 MAPK phosphorylation showed a 4-fold increase in controls ( Figure 6A, lane 5) , this was increased Ϸ7-fold in Rab7a-depleted cells ( Figure  6C, lane 6) . Thus Rab7a depletion caused Ϸ1.8to 2-fold changes in VEGF-A-stimulated VEGFR2 and p42/44 MAPK phosphorylation levels. Analysis of p42/44 MAPK localization in Rab7a-depleted cells using microscopy showed no morphological difference to control scrambled siRNAtransfected cells (supplemental Figure IV) .
A key question is whether Rab activity is required for physiological responses by the endothelium. A key endothelial function is cell migration required for vasculogenesis, angiogenesis, and wound healing. 31 To test this idea, we depleted Rab5 or Rab7 levels using RNAi and monitored endothelial cell migration in different types of cell growth media containing or lacking VEGF-A ( Figure 6D ). In control cells transfected with a scrambled siRNA duplex, there was substantial migration in media containing excess VEGF-A. However, in serum-free media lacking VEGF-A, there was only Ϸ20% cell migration compared to that observed in the presence of VEGF-A. Depletion of Rab7a showed pronounced inhibition of VEGF-A-stimulated migration in any of the 3 media conditions, with Ϸ50% to 60% cell migration compared to controls ( Figure 6D) . Surprisingly, depletion of Rab5a levels using RNAi showed the opposite effect with either a Ϸ25% increase (full growth media) or a Ϸ60% increase (VEGF-A-supplemented media) in cell migration compared to control cells ( Figure 6D ).
Discussion
Herein, we provide evidence for a Rab-dependent mechanism for regulating VEGFR2 trafficking and signaling from endosomes in primary endothelial cells. Manipulation of GTPase activity through overexpression of GFP-tagged wild-type or mutant Rab7a proteins perturbed endothelial VEGFR2 trafficking, degradation, and signaling. Intriguingly, Rab7a depletion decreased VEGFR2 tyrosine autophosphorylation on residue Y1175, a characteristic signature in VEGFR2mediated activation and signaling. 32 This correlated with Ϸ50% decrease in VEGF-A-stimulated endothelial cell migration after Rab7a depletion, suggesting a requirement for Rab7a in VEGFR2-mediated signaling. However, in Rab7adepleted cells, there was increased p42/44 MAPK levels 30 minutes after VEGF-A addition, suggesting increased signaling through this arm of the pathway. A likely explanation is that VEGFR2-regulated signaling to p42/p44 MAPK occurs at the early endosome and is prolonged in Rab7a-depleted cells as VEGFR2 cannot progress toward lysosomal degradation. A different study has also argued that VEGFR2regulated p42/44 MAPK activation can occur via endosomes 33 rather than solely at the plasma membrane. RTKs such as EGFR, 28, 29 PDGFR, 34 c-Met, 35 and TrkA 14,36,37 have also been found to be capable of signaling from early endosomes. These lines of evidence suggest existence of at least 2 distinct VEGF-A and VEGFR2-regulated signaling pathways, one of which regulates cell migration, and this is distinct from the MAPK signaling pathway.
Our findings also support requirement for the Rab5a GTPase in early endosome sorting of both quiescent and activated VEGFR2. Both Rab5a and VEGFR2 showed substantial colocalization with a marker for early endosomes, EEA1. VEGF-A stimulation caused activated VEGFR2 accumulation in early endosomes with a block in subsequent lysosomal degradation of VEGFR2. Intriguingly, Rab5a depletion caused Ϸ25% to 60% increase in VEGF-A-stimulated endothelial cell migration, suggesting that VEGFR2mediated signaling in prolonged under such conditions. Rab5a expression in immortalized epithelial cells also causes quiescent EGFR accumulation in endosomes, but it is unclear whether this is attributable to increased endocytosis or inhibition of EGFR recycling. 38 Rab5a is also implicated in clathrin-coated pit formation 39 suggesting that this GTPase may act at multiple steps from the plasma membrane to early endosomes. However, we cannot exclude the possibility that Rab5aQ79L inhibits activation of VEGFR2, leading to abrogation of activated VEGFR2 trafficking. In addition, we observed enhanced VEGFR2 phosphorylation on knockdown of Rab5a.
Downstream of early endosomes, Rab7a was implicated in activated VEGFR2 egress out of late endosomes toward degradation in lysosomes. The dominant-negative GDPbound Rab7aT22N mutant perturbs late endosome trafficking 40, 41 and renders late endosomes inaccessible to activated RTKs. In transformed epithelial cells, Rab7a perturbation decreased both EGF and EGFR degradation and modulation of EGFR signaling. 28 Similarly, Rab7a-linked effects causes endosomal accumulation of TrkA 37 and viral spike glycoproteins. 42, 43 Identification of Rab-mediated steps in the VEGFR2 endocytic itinerary argues for a network of interactions that impact on vascular features such as angiogenesis and blood pressure. Indeed, Rab GTPase activity can be modulated by RTK activation to provide a positive feedback mechanism. 19, 44 VEGFR2 trafficking through the endocytic pathway argues for signaling from plasma membrane and later compartments with p42/44 MAPK activation occurring on endosomes. Intriguingly, a recent report suggests that the strength of a c-Met-derived signal is dependent on plasma membrane or endosome location with major consequences for nuclear gene expression. 45 VEGF-A stimulation of Rab5aor Rab7a-depleted cells suggest lesser effects on endothelial cell proliferation (A.F. Odell and S. Ponnambalam, unpublished data, 2009), but this requires further study. The evidence from our study leads us to conclude that different effectors are recruited to VEGFR2 to impose a spatiotemporal framework for trafficking and signaling leading to changes in vascular physiology in response to VEGF-A ligand. Investigation of the link between Rab GTPase activity and VEGF-A receptor activation may provide routes to modulate vascular physiology in human health and disease. 
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